Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly

References

• Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A. Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016;263:1241–54.
   PubMed Web of Science ®Google Scholar
• Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9:303–9.
   PubMedGoogle Scholar
• Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603–15.
   PubMed Web of Science ®Google Scholar
• Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001;187:81–9.
   PubMed Web of Science ®Google Scholar
• Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. Bmj. 2014;349:g3743.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004–9.
   PubMed Web of Science ®Google Scholar
• Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:638–42.
   PubMed Web of Science ®Google Scholar
• Dedic SI, Stevic Z, Dedic V, Stojanovic VR, Milicev M, Lavrnic D. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol Res. 2012;34:576–80.
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681–5.
   PubMed Web of Science ®Google Scholar
• Korner S, Kollewe K, Ilsemann J, Muller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:647–54.
   PubMed Web of Science ®Google Scholar
• Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261:1949–56.
   PubMed Web of Science ®Google Scholar
• Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. Pharmacoepidem Drug Safe. 2008;17:1068–76.
   PubMed Web of Science ®Google Scholar
• Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Safety. 2007;30:515–25.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:241–5.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3:413–7.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174:860–70.
   PubMed Web of Science ®Google Scholar
• McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Ijms. 2014;15:20607–37.
   Google Scholar
• Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D, et al. Prospective analysis of association between use of statins and melanoma risk in the Women’s Health Initiative. Cancer. 2012;118:5124–31.
   PubMed Web of Science ®Google Scholar
• Duncan RE, El-Sohemy A, Archer MC. Statins and the risk of cancer. JAMA. 2006;295:2720.
   PubMedGoogle Scholar
• Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:877–88.
   PubMed Web of Science ®Google Scholar
• Bonito A BC, Eicheldinger C, Carpenter L. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. Rockville, MD: Agency for Healthcare Research and Qaulity and Center for Medicare and Medicaid Services; 2008.
   Google Scholar
• Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997–2011. Neurol Clin Pract. 2013;3:313–20.
   PubMedGoogle Scholar
• Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:433–9.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Lash TL. Statins and amyotrophic lateral sclerosis-the level of evidence for an association. J Intern Med. 2009;266:520–6.
   PubMed Web of Science ®Google Scholar
• Bykov K, Yoshida K, Weisskopf MG, Gagne JJ. Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 2017;26:294–300.
   PubMed Web of Science ®Google Scholar
• Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, et al. Statins, plasma cholesterol, and risk of Parkinson’s disease: a prospective study. Mov Disord. 2015;30:552–9.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Bmj. 2010;340:c2197.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–90.
   PubMed Web of Science ®Google Scholar
• Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, et al. Time to diagnosis in the National registry of veterans with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:125–32.
   PubMed Web of Science ®Google Scholar
• Gallo V, Wark PA, Jenab M, Pearce N, Brayne C, Vermeulen R, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. 2013;80:829–38.
   PubMed Web of Science ®Google Scholar
• O'Reilly EJ, Wang M, Adami HO, Alonso A, Bernstein L, van den Brandt P, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19:396–406.
   PubMed Web of Science ®Google Scholar
• Wang H, O’Reilly ÉJ, Weisskopf MG, Logroscino G, McCullough ML, Thun MJ, et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch Neurol. 2011;68:207–13.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wilson PW, Kannel WB. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation. 2008;117:3031–8.
   PubMed Web of Science ®Google Scholar
• Lu H, Le WD, Xie YY, Wang XP. Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol. 2016;14:314–21.
   PubMed Web of Science ®Google Scholar
• van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88:64–75.
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Yoshii Y, Ikeda K. Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice. Amyotroph Lateral Scler. 2009;10:405–9.
   PubMed Web of Science ®Google Scholar
• Lee SH, Choi NY, Yu HJ, Park J, Choi H, Lee KY, et al. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol Neurobiol. 2016;53:695–705.
   PubMed Web of Science ®Google Scholar
• Murinson BB, Haughey NJ, Maragakis NJ. Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet Disord. 2012;13:100.
   PubMed Web of Science ®Google Scholar
• Su XW, Nandar W, Neely EB, Simmons Z, Connor JR. Statins accelerate disease progression and shorten survival in SOD1(G93A) mice. Muscle Nerve. 2016;54:284–91.
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010;11:111–21.
   PubMed Web of Science ®Google Scholar
• Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, et al. Preferential PPAR-alpha activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet. 2016;25:317–27.
   PubMed Web of Science ®Google Scholar